Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey
25 September 2019
While the rise of antimicrobial resistance (AMR) has been recognised as a major public health problem, the value of vaccines to control AMR is poorly defined. This expert survey was launched with the aim of informing the 2018 Vaccine Investment Strategy through which Gavi, the Vaccine Alliance prioritises future vaccine funding. This exercise focused on both vaccines currently supported by Gavi and under consideration for future funding.
Further reading: F1000Research
Author(s): Maya Malarski, Mateusz Hasso-Agopsowicz, Adam Soble, Wilson Mok, Sophie Mathewson, Johan Vekemans
Effective Surveillance Healthy Patients
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!